➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Colorcon
Johnson and Johnson
McKinsey
Baxter

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Patent: 9,855,371

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 9,855,371
Title:Bioresorbable stent
Abstract: Disclosed herein is a high strength, bioresorbable wall thickness suitable for use in an endoprosthesis such as a stent that is produced by first forming a wall thickness by melt processing or solution processing one or more bioresorbable materials into a tubular shape; drawing the shape from shorter length to an optimum longer length and reducing the diameter from a larger diameter to a smaller diameter to orient the molecular chains of the material; fabricating a stent from the tube formed of the oriented material by cutting a strut pattern in its wall thickness; covering the stent\'s struts with at least one coating to delay degradation of the bioresorbable material; covering the stent\'s struts with one or more controlled release active ingredients to minimize the risk of restenosis or other side effects; crimping the stent onto a balloon catheter assembly; delivering the stent into an anatomical lumen via percutaneous methods to a treatment location; radially expanding the stent from a smaller size to a larger size at the treatment location wherein the stent temporarily supports the anatomical lumen; and removing the catheter from the lumen.
Inventor(s): Scanlon; John James (Wilmington, DE), Scanlon; Catherine Ann (Wilmington, DE)
Assignee:
Application Number:14/263,851
Patent Claims:see list of patent claims

Details for Patent 9,855,371

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 1994-12-22 ⤷  Free Forever Trial 2039-02-26
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Free Forever Trial 2039-02-26
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Free Forever Trial 2039-02-26
Eli Lilly And Company ERBITUX cetuximab Injection 125084 2004-02-12 ⤷  Free Forever Trial 2039-02-26
Eli Lilly And Company ERBITUX cetuximab Injection 125084 2007-03-28 ⤷  Free Forever Trial 2039-02-26
Genentech, Inc. AVASTIN bevacizumab Injection 125085 2004-02-26 ⤷  Free Forever Trial 2039-02-26
Amgen, Inc. VECTIBIX panitumumab Injection 125147 2006-09-27 ⤷  Free Forever Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Express Scripts
Harvard Business School
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.